MedTrace Logo

Study of Vudalimab or Pembrolizumab in Combination With Chemotherapy as First-line Treatment in Patients With Advanced NSCLC

NCT06173505 · Status: TERMINATED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 28

Last updated 2026-03-13

No results posted yet for this study

Summary

The purpose of this study is to identify the recommended dose of vudalimab to be used in combination with chemotherapy (Part 1) and to evaluate the efficacy and safety of vudalimab plus standard of care chemotherapy relative to pembrolizumab plus chemotherapy (Part 2) as first-line treatment in patients with nonsquamous non-small cell lung cancer (NSCLC).

Conditions

  • Nonsquamous Non-small Cell Lung Cancer

Interventions

COMBINATION_PRODUCT

Vudalimab + Carboplatin + Pemetrexed

Vudalimab intravenous + carboplatin intravenous + pemetrexed intravenous

COMBINATION_PRODUCT

Pembrolizumab + Carboplatin + Pemetrexed

Pembrolizumab intravenous + carboplatin intravenous + pemetrexed intravenous

Sponsors & Collaborators

  • Xencor, Inc.

    lead INDUSTRY

Principal Investigators

  • Jolene Shorr · Executive Director, Clinical Development

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-12-27
Primary Completion
2025-12-24
Completion
2025-12-29
FDA Drug
Yes

Countries

  • United States
  • Belgium
  • Greece
  • Malaysia
  • Netherlands
  • Portugal
  • Spain
  • Taiwan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06173505 on ClinicalTrials.gov